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Background: A proposed mechanism of chronic pain is dysregulation between the main inhibitory (GABA) and
excitatory (glutamate) neurometabolites of the central nervous system. The level of these neurometabolites ap-
pears to differ in individual studies of people with pain compared to pain-free controls across different pain
conditions. However, this has yet to be systematically investigated.
Aims: To establish whether GABA, glutamate, glutamine and Glx levels differ across pain conditions when
compared to pain-free controls.
Methods: Five databases were searched. Studies were included if they investigated: 1) A pain condition compared
to control. 2) Reported GABA, glutamate, glutamine or glutamate/glutamine level. 3) Used 1H-Magnetic Reso-
nance Spectroscopy (Prospero Project ID CRD42018092170). Data extracted included neurometabolite level, pain
diagnosis, and spectroscopy parameters. Meta-analyses were conducted to establish the difference in neuro-
metabolite level between participants with pain and pain-free controls for different pain conditions. The MRS-Q
was developed from existing clinical consensus to allow for the assessment of quality in the included studies.
Results: Thirty-five studies were included investigating combinations of migraine (n¼ 11), musculoskeletal pain
(n¼ 8), chronic pain syndromes (n¼ 9) and miscellaneous pain (n¼ 10). Higher GABA levels were found in
participants with migraine compared to controls (Hedge's G 0.499, 95%CI: 0.2 to 0.798). In contrast, GABA levels
in musculoskeletal pain conditions (Hedge's G 0.189, 95%CI: 0.530 to 0.153) and chronic pain syndromes
(Hedge's G 0.077, 95%CI: 1.612 to 1.459) did not differ from controls. Results for other brain neurometabolites
revealed significantly higher levels for glutamate in participants with migraine and Glx in chronic pain syndromes
compared to controls.
Conclusion: These results support the theory that underlying neurometabolite levels may be unique in different
pain conditions and therefore representative of biomarkers for specific pain conditions.1. Introduction
Two key neurometabolites implicated in the pathophysiology of pain
are glutamate and gamma-aminobutyric acid (GABA). Glutamate is the
principal excitatory neurometabolite in the central nervous system, and
is involved in many metabolic pathways (Rae, 2014; Ramadan et al.,es, University of Sydney, 75 East
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2006; Rae, 2014) and is considered an important regulator of the balance
between excitation and inhibition in the brain (Petroff, 2002). Both
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or too little of the neurometabolite, have been implicated in clinical
conditions, such as chronic pain (MacDermott, 2001; Zunhammer et al.,
2016).
In-vivo quantification of these neurometabolites is possible through
proton magnetic resonance spectroscopy (1H-MRS). 1H-MRS is a non-
invasive neuroimaging technique that allows for the separation of neu-
rometabolites based on their chemical structure. Separation of spectra is
possible through observing the radiofrequency signal detected from
hydrogen nuclei spins and their chemical environment when placed in a
magnetic field (Puts and Edden, 2012). Accordingly, neurometabolites
can be separated along an x-axis dependent on their chemical specific
radiofrequency, otherwise known as their chemical shift. The strength of
this signal is reflective of the level of neurometabolite. Whilst 1H-MRS
has been helpful in quantification of many neurometabolites, the mea-
surement of GABA and glutamate have their own specific challenges.
Quantification of GABA is problematic due to its low concentration
(1–2mM (Govindaraju et al., 2000; Petroff, 2002)), and spectral overlap
with other more abundant neurometabolites such as creatine at 3 ppm
(Puts and Edden, 2012). To resolve GABA, J-difference editing can be
used to selectively edit the signal of interest. J-difference editing of GABA
uses frequency selective ‘editing’ pulses, applied to the 1.9 ppm GABA
signal, which in turn, selectively refocused the GABA signal at 3 ppm, but
not the creatine signal. The most widely used sequence for measuring
GABA is MEGA-PRESS (Mikkelsen et al., 2017; Mullins et al., 2014).
Here, editing pulses are applied on-resonance (edit-ON) at 1.9 ppm in
half the acquisition, and not in the other half (edit-OFF). The difference
spectrum contains only those signals affected by the editing pulses,
revealing a quantifiable GABA signal at 3 ppm (for a review, see Puts and
Edden, 2012). However, various implementations of the sequence exist,
utilizing different radio-frequency pulses and timings (Mikkelsen et al.,
2017, 2019; Saleh et al., 2019). One limitation of J-difference editing is
macromolecule contamination meaning that studies using this editing
report GABAþ rather thanmeasures of GABA only. This can be overcome
with symmetrical editing or measured macromolecule baselines which
reflect a more refined measure of GABA (Edden et al., 2012; Mikkelsen
et al., 2018a).
There is little consensus as to the best way to measure glutamate.
Glutamate is present at higher concentrations (12mM (Choi et al., 2006))
than GABA, however, difficulties separating it from glutamine (1–4mM)
and glutathione (2–3mM (Rae, 2014)) have been highlighted. Whilst
some studies estimate glutamate alone (Schubert et al., 2004), others
choose to estimate Glx, the combined measure of glutamate and gluta-
mine, although the signal also contains some glutathione. Glx is
measured either from edited MRS (Sanaei Nezhad et al., 2017) or from
short echo time PRESS (30ms) (Gonzales de la Aleja et al., 2013). Other
techniques specific to measuring glutamate (separating it from gluta-
mine), including TE-averaging, also exist (Hurd et al., 2004).
Several 1H-MRS studies to date have demonstrated changes in GABA
and glutamate in pain conditions compared to controls. However, the
direction of concentration change is inconsistent across pain conditions.
For example, Aguila et al. (2015) demonstrated an increase in GABA
levels in individuals with migraine compared to controls. In contrast,
GABA levels were decreased in people with fibromyalgia (Foerster et al.,
2012) and chronic pelvic pain (Harper et al., 2018). Similarly, glutamate
levels were higher in people with migraine compared with controls
(Gonzales de la Aleja et al., 2013; Zielman et al., 2017), however, lower
in people with low back pain (Gussew et al., 2011). The variability in
these data suggest that there may be a unique neurometabolite signature
for each pain condition. However, to-date these data have not been
systematically appraised.
An alternative explanation for the variability of neurometabolite
levels between pain conditions and MRS studies could be reflective of the
quality of the magnetic resonance (MR) acquisition and analysis. This
includes the 1H-MRS sequence utilised. For example Bridge et al. (2015)
used an unedited sequence and demonstrated a 10% decrease in GABA2level in individuals with migraine compared to controls (Bridge et al.,
2015). Conversely, Aguila et al. (2015) used an edited sequence and
demonstrated a significant increase in GABA level in people with
migraine compared to controls. More importantly, it is well-established
that reporting of acquisition parameters is important for allowing of
interpretation and reproducing prior studies.
The role of different brain regions in pain processing have been
extensively studied using a variety of imaging and in vitro methods in
both humans and animals It is therefore possible that the level of neu-
rometabolites differ between brain regions. Differences have been
demonstrated in people with fibromyalgia (Foerster et al., 2012), where
the same individuals demonstrated an increase in GABA level in the
insula but not the anterior cingulate cortex (ACC). Alternative explana-
tions for these differences include; variation in signal to noise ratio
dependent on location of brain region being scanned, the composition of
the voxel in terms of grey and white matter, and the distribution of GABA
and glutamate receptors in that specific brain region. Advances in anal-
ysis techniques and the introduction of volume-based correction allows
better understanding of these factors, however, they have not been uni-
formly applied across studies, and therefore their impact must be
considered when synthesizing results from studies.
The primary aim of this review therefore was to determine whether
GABA, glutamate, glutamine and Glx levels differ across pain conditions
compared to pain-free controls. The secondary aim was to report on the
quality of the MR data acquired in the literature in this field and then, to
determine whether the quality of reporting, or brain region, influences
brain neurometabolite levels. Assessing appropriate acquisition param-
eters necessitated us to develop the MRS-Q tool for systematic review of
1H-MRS acquisitions, as no such tool previously existed. The de-
terminants are based on prior consensus.
2. Methods
2.1. Protocol registration
This reviewwas conducted in adherence with the Preferred Reporting
Items for Systematic Reviews and Meta-analysis statement (PRISMA)
(Moher et al., 2015) and was registered prospectively on Prospero
(CRD42018092170).
2.2. Eligibility criteria
Studies were included if they used 1H-MRS of the brain to report
measures of GABA, glutamate, glutamine or the combination measure of
glutamate and glutamine i.e. Glx. Among these studies were Spectro-
scopic Imaging (MRSI) studies. Studies were required to have recruited
human participants who had a pain condition that was compared with
healthy pain-free controls. Included studies were of primary research
design, such as cross-sectional, longitudinal, interventional or case series,
and written or translated into English via Google Translate.
Studies were excluded if they used other forms of spectroscopy e.g.
phosphorous MRS or examined other tissues, such as the spinal cord.
Studies that investigated animals or conditions which were primarily
psychological disorders without pain as a predominant feature (e.g. post-
traumatic stress) were also excluded, as were literature reviews or con-
ference proceedings.
2.3. Search methods for identification of studies
A comprehensive search strategy was derived and piloted with
assistance from the University's librarian. The full search strategy and
search terms are attached in Appendix 1. In brief we combined MeSH
headings and key words for magnetic resonance spectroscopy (for
example: magnetic resonance imag*, NMR- Spectroscopy, MEGA-PRESS)
AND neurometabolites (for example: GABA or glutamate or glutamine
or Glx, brain neurochemical*, metabolite*) AND pain (for example:
A.L. Peek et al. NeuroImage 210 (2020) 116532chronic pain (expanded), musculoskeletal pain).
OVID MEDLINE, EMBASE, WEB of SCIENCE, CINAHL and Pubmed
were electronically searched without any restrictions to date, study
design or language (inception to September 4, 2019). Reference lists of
included studies and systematic reviews in this field were searched to
ensure key studies had not been missed.
2.4. Study selection
A two stage approach was used to screen studies for inclusion (Furlan
et al., 2009). In the first stage, two reviewing teams (AP) and (MA or AL
or TR or JW) independently screened titles and abstracts to identify titles
for full text retrieval. Where there was uncertainty, the full text was
requested. In the second stage, two reviewers (AP) and (MA or AL or TR
or JW) independently assessed the full text of all studies to determine
their eligibility. Disagreements were discussed and resolved by a third
independent reviewer (AL or TR). Reasons for exclusion were docu-
mented and duplicates were removed.
2.5. Data extraction
Data were extracted in duplicate by 2 reviewers (AP, JW) using a
standardised form (Appendix 2). Authors were contacted for missing data
or raw data when data was only presented graphically. When authors
failed to respond, graphical results were extracted using on-screen cal-
lipers (Screen Callipers Version 4.0). Where non-parametric statistics
were reported, means and SD were imputed using methods recom-
mended in the Cochrane handbook (Higgins et al., 2011). Only primary
analyses were extracted from the included studies. In the case of longi-
tudinal or interventional studies, only baseline data were extracted. Data
from different brain regions of the same individual was interpreted as
being independent, and therefore extracted separately for each brain
region (Aoki et al., 2012; Schur et al., 2016). A secondary meta-analysis
(not shown) averaged across brain regions of the individual.
Data were extracted into 4 tables: 1) spectroscopy parameters, where
data extracted included scanner make, acquisition parameters e.g. voxel
size and location, TR, TE and post processing details such as software and
fitting methods (see Appendix 2); 2) neurometabolite levels, where the
primary outcome of interest (mean (SD)) of GABA, glutamate, glutamine
or Glx levels for subjects with pain and control subjects; 3) participant
characteristics, including age, sex, pain condition, excluded comorbid-
ities, and 4) Bibliometric data, including authors, year of publication,
country, funding sources and if prospectively registered (Appendix 2).
2.6. Quality metrics
2.6.1. AXIS
Two quality measures were used. Firstly, the modified Appraisal tool
for Cross-sectional studies (AXIS) (Downes et al., 2016) was used to
determine the methodological quality of the research design (Appendix
3). The modified AXIS was piloted on 1H-MRS studies prior to inception
of the review (AL, AP, JW, NP). Two reviewers (AP, NP or JW) inde-
pendently assessed the quality of each included paper. Disagreements
were subsequently discussed and resolved by a third reviewer (AL).
2.6.2. MRS-Q
Secondly, the quality of the 1H-MRS acquisition method was
assessed. Although two recent 1H-MRS white papers suggest that re-
searchers use standardized acquisition and analysis metrics (Mullins
et al., 2014; Wilson et al., 2019) to-date there are no published stan-
dardized tools to objectively evaluate the quality of spectroscopic
acquisition. For assessment, this necessitated the development of a new
quality appraisal tool (MRS-Q) for this review, based upon consensus
papers and expert opinion on best-practice (Harris et al., 2017; Mikkelsen
et al., 2017, 2019; Mullins et al., 2014; Wilson et al., 2019). The MRS-Q
evaluates 12 and 13 parameters for unedited and edited studies3respectively. The MRS-Q has three parts, Part 1 checks whether appro-
priate sequences and adequate parameters were used to accurately detect
the neurometabolite of interest. The criteria in Part 1 include quality
parameters that are considered fundamental to producing good quality
spectra. Two of these parameters, appropriate sequence and adequate pa-
rameters, were also used to determine the quality of acquisition for the
purpose of our sensitivity analysis. Part 2 evaluates whether sufficient
quality checks were utilised such as reporting full width at half maximum
(FWHM) and the visualisation of data. In Part 3, details of study design
such as sample size calculations and post processing methods were
appropriate and explicitly reported are evaluated. As such, this tool re-
ports on both acquisition and the adequate reporting of this information
(e.g. for allowing reproducibility of such studies). Each study was
assessed independently by 2 reviewers (AP,NP). The cut-off points and
rationale for each of the criteria are displayed in Table 1. Only studies
that reported using adequate spectroscopy parameters for the neuro-
metabolite of interest were considered high-quality and used in the
sensitivity analysis (see Data synthesis: secondary aims).
2.7. Data synthesis and analysis
2.7.1. Primary aim
In line with the review's primary aim; to determine if brain neuro-
metabolites are different across pain conditions, it was decided a priori to
categorise studies into one of four pain categories for analysis. The cat-
egories were migraine, musculoskeletal pain, chronic pain syndromes or
miscellaneous pain for studies that did not fit into the above categories.
The migraine group was inclusive of any form of painful migraine or
headache listed in the ICHD 3b. Musculoskeletal pain was defined as any
condition diagnosed from a single anatomical site, and likely to be driven
by a nociceptive input e.g. low back pain, knee osteoarthritis. Conversely,
chronic pain syndromes were defined as any widespread chronic pain
condition affecting multiple regions with a non-specific musculoskeletal
diagnosis, that is predominately associated with central processing ab-
normalities (Arnold et al., 2016) e.g. fibromyalgia, complex regional pain
syndrome, the remaining studies were considered as miscellaneous pain
and encompassed any other non-musculoskeletal pain conditions such as
abdominal pain, spinal cord injury with painful neuropathy. From
here-on the group name will be used to refer to individuals who expe-
rience these particular conditions e.g. people with migraine (migraine).
Data was labelled according to brain region investigated. It was
decided a priori that labelling would be regardless of hemisphere
investigated, unless a single study contributed both a left and right data
set. Nomenclature of brain region was simplified in terms of region, for
example the dorsolateral prefrontal cortex was labelled and identified as
the prefrontal cortex.
Meta-analysis was performed using Comprehensive Meta-analysis
software (Borenstein et al., 2005) on studies pooled by neuro-
metabolite, and sub-grouped by pain condition to allow comparison of
neurometabolite level between pain conditions. Because the “miscella-
neous” group were a heterogeneous category, these results in this group
were not pooled in the meta-analysis. Standardised mean differences and
95% confidence intervals (Hedge's G) were used to compare the pain
groups to the painfree controls to allow for data presented in different
units (mmol, IU, ratios).
Results were analysed by neurometabolite and sub-grouped by pain
type (migraine, musculoskeletal pain, chronic pain syndromes) regard-
less of brain region studied. Where multiple results were presented for
the same neurometabolite preference was given to results of actual
concentration or institutional units over ratios. Heterogeneity was
assessed using the i2 test and a random-effects model was implemented to
compensate for variation in acquisition parameters, voxel location and
the selective use of partial volume correction.
2.7.2. Secondary aims
To investigate the review's secondary aims, firstly summary measures
Table 1
Criteria and rationale of the MRS-Q toola.
Criteria Setting Rationale
1. Parameters Scanner Strength Edited for GABA: Over 3T
Unedited: 3T preferable
Scanning at 3T and above provides a higher signal-to-noise ratio,
with increased spatial and temporal resolution. Reducing
spectral overlap of Glu, Gln, and GABA (Di Costanzo et al., 2007;
Wilson et al., 2019)
Appropriate Sequence: Edited for GABA: MEGA-PRESS, MEGA-semi
LASER, other editing
To accurately quantify GABA a specific editing sequence must be
implemented (Mullins et al., 2014). EDITINGSCHOOL b, Expert
opinion c
*Used to determine quality Unedited: PRESS or vendor specific PRESS, semi-
LASER or STEAM
Common clinical implementation agreed through consensus
opinion (Wilson et al., 2019)
Adequate Parameters:
*Used to determine quality
Edited for GABA: Averages over 240 This number of averages are required due to the low amplitude of
signal due to the typically low concentration of GABA and
splitting due to coupling (Mikkelsen et al., 2018b)
EDITINGSCHOOL b
TE: GABAþ 68, GABA 80 (68 S) *See Appropriate TE below
Voxel Size ~27ml The voxel size required to quantify GABA as a compromise
between localization and adequate signal to noise (Mullins et al.,
2014)
Unedited: 128 Av, 15 15 15mm3 voxel, 3T;
64 Av, 20 20 20 mm3 voxel, 3T;
256 Av, 15 15 15 mm3 voxel 1.5T;
In order to produce adequate SNR, the number of averages need
to be increased when using lower strength scanners, or smaller
sized voxels (Wilson et al., 2019)
128 Av, 20 20 20 mm3 voxel, 1.533 Common clinical implementation agreed through consensus
opinion (Wilson et al., 2019)
MRSI: 3T, 16 16 matrix, voxel 15 mm3 TR 1500,
Data Points Edited for GABA: NA –
Unedited: 1024 complex data points from 2000Hz Common clinical implementation agreed through consensus
opinion (Wilson et al., 2019)
Appropriate TE Edited for GABA: 68ms or 80ms 68ms is optimal for GABA- due to complete inversion in the ON
acquisition. (Rothman et al., 1993) 80ms for macromolecule
editing (Edden et al., 2012) Mullins et al., 2014 e.
EDITINGSCHOOL b
Unedited: 20/30ms Common clinical implementation agreed through consensus
opinion (Wilson et al., 2019)
2. Quality Measures Quality measure Reported Shim or FWHM (Full Width Half
Maximum)
Poor shimming leads to aberrant quantification. Linewidth is
known to affect fitting and be an index of data quality (Wilson
et al., 2019)
Quality measure Fit Error Calculation reported While the format is less-important, fit error reports on the quality
of the spectra and/or appropriate fitting methods. While fit-error
cut offs are proposed (e.g. <20% CRLB for LC model analysis
(Cavassila et al., 2001)) we did not stipulate specific cut offs here.
Data visualisation A visual display of at least one data set Recommendations are that visual display of spectra (e.g. an
example spectrum, all spectra) are reported in a figure (e.g.
Zielman et al., 2017)
Partial volume correction Partial Volume Corrected- not just for grey matter For water-referenced data, partial volume can substantially affect
data quantification and could be a prominent driver of group
differences. In addition, only correcting for grey matter is
deemed inappropriate (Gasparovic et al., 2006; Harris et al.,
2015; Mikkelsen et al., 2016; Porges et al., 2017)
EDITINGSCHOOL b
Scanner drift Frequency Drift Reported This has been shown to be of particular importance for edited
MRS (Harris et al., 2014; Mikkelsen et al., 2017; Near et al.,
2015)
3. Study Design Power calculation Report how sample size was determined Allows demonstration of whether the study is adequately
powered to detect between group difference- reducing the
chance of type I and II error (Nayak, 2010)
Frequency/phase corrected Reported either frequency or phase correction Frequency and phase correction prior to fitting is strongly
recommended, and is key for edited MRS (Mullins et al., 2014;
Wilson et al., 2019) EDITINGSCHOOL b, Expert opinion d
a Template available for use from http://doi.org/10.17605/OSF.IO/8S7J9.
b EDITINGSCHOOL was held in December 2018 and focused on edited MRS. Expert instructors attended (http://www.gabamrs.com/blog/2018/10/12/editingschool
-final-schedule).
c Co-author NP.
d Wilson et al., 2019 Consensus document agreed on by 49 MRS experts.
e Mullins et al., 2014 Consensus document written from a meeting of a number of specialist groups in 2011 in the UK documenting current “minimal best practice”.
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(Tables 2–4) (University of York, 2009) Secondly, a sensitivity analysis
was conducted, where the primary meta-analysis was repeated only on
the studies that satisfied the use of minimal best practice in terms of
appropriate sequence and adequate spectroscopy parameters as deter-
mined by the appropriate sequence and adequate parameters subsections of
the MRS-Q (Table 1, rows 2, 3). To determine the impact of brain region
on neurometabolite levels, studies were grouped broadly by brain region.
Results were pooled where there were two or more homogeneous studies4of a particular brain region within a pain condition. Finally, post-hoc
meta-analyses were conducted, where data from multiple brain regions
of the same individual were averaged and included within the analysis.
3. Results
3.1. Study selection
An initial search retrieved 8022 studies. Following removal of
Table 2
Study characteristics.
Strength (scanner)/Sequence/
(TR/TE)/Avs/Processing
Region/Voxel size (ml) Neurometabolites Participants: Number/Pain/%Female/
Age/Duration
Controls: Number/%Female/Age
Aguila et al. (2015) 3T (GE)/MEGA-PRESS/(1800/
68)/256/Gannet (GABA), Tarquin
(Glu, Gln)
PCG/27ml GABAþ, Glu, Gln n ¼ 19/Migraine (ICHD II), 1 attack a
monthþ/70%F/33 IQR (28.2–47.2) yrs/
180 months IQR (60–288)
n¼ 19/70%F/30 IQR (26.5–47.5)
yrs
As-Sanie et al. (2016) 3T (GE)/PRESS/(3000/3*)/-/LC
model
R ant Ins, R post Ins/ 12ml Glx (NAA) Group 1: n¼ 15/Chronic pelvic pain with
endometriosis/100%F/26.7 (6.6) yrs/5.5
(3.5–9.5) yrs
Group 2: n¼ 6/Chronic pelvic pain
without endometriosis/100%F/24.2 (4.6)
yrs/3.75 (0.9)yrs
Matched to Group 1: n¼ 14/
100%F/26.5 (6.6) yrs
Matched to Group 2: n¼ 11/
100%F/24.2 (4.0) yrs
Bathel et al. (2018) 3T (P)/MEGA-PRESS/(2000/68)/
320/Gannet
PRESS/(2000/30)/32/LC model
Occ/27ml, R Thal/22.5 ml GABAþ
Glx (NAA, Cr)
n¼ 15/Migraine without aura (ICHD-II),
>2 a month, pain-free 72 h prior and 48 h
after scanning/80%F/35.2 (10.8) yrs/-
n¼ 15/80%F/33.4 (8.5) yrs
Bednarska et al. (2019) 3T (P)/MEGA-PRESS/(2000/
68)/-/LC Model
L ant Ins, R ant Ins/24ml GABAþ, Glx n¼ 39/IBS/100%F/32.1 (18–57) yrs/- n¼ 21/100%F/32.1 (20–55) yrs
Bigal et al. (2008) 4T (V)/3D-LASER**/(2000/72)
**/-/-
Occ/13.5 ml GABA Group 1: n¼ 9/Migraine with aura/84.7%
F/34.1 (95% CI 27.9–40.2) yrs/-Group 2:
n¼ 10/Migraine without aura/84.7%F/
41.4 (95% CI 30.5–52.2) yrs/-
n¼ 9/84.7%F/26.5 (95% CI
22.4–30.5) yrs
Bridge et al. (2015) 3T (Sie)/SPECIAL/(11.2/4.68)/
128/LCModel
Occ/8ml GABA, Glu n¼ 26/Migraine with aura (IHS)/100%F/
33 (8) yrs/-
n¼ 13/100%F/30 (6) yrs
Chan et al. (2019) 3T (Sie)/MEGA-PRESS/(1500/
68)/192/Gannet
Occ/15ml GABA, Glx Group 1: n¼ 9/Migraine with aura/88.9%
F/31 (95% CI 21–42) yrs/-Group 2: n¼ 7/
Migraine without aura/71.4%F/31.1 (95%
CI 20–49) yrs/-
n¼ 16/50%F/27.1 (95% CI
20–34) yrs
Di Pietro et al. (2018) 3T (P)/MEGA-PRESS/(2000/68)/
200/jMRUI, AMARES (GABA),
QUEST (Cr)
Thal/8 ml GABA, (Cr, Other neurometabolites) n¼ 20/Chronic orofacial neuropathic
pain/65%F/50.1 SEM (4.4) yrs/>3yrs
n¼ 20/65%F/42.2 SEM (2.9) yrs
Fayed et al. (2010) 1.5T (GE)/Probe P/(2000/35)/
128/LC model
L SM1, L and R Thal, L and R
hippoc, PCG/8ml
Glx, (Cr, Cho, mI, NAA) n¼ 10/Fibromyalgia (ACR)/80%F/40
(6.2) yrs/1.6 (0.3) yrs
n¼ 10/80%F/37.8 (8.7) yrs
Fayed et al. (2012) 1.5T (GE)/Probe P/(2000/35)/
128/LC model
PCG, pos Ins, L and R hippoc/8ml Glx, Glu, (NAA, Cr, mI, tChol,
tNAA)
Group 1: n¼ 10/Fibromyalgia (ACR)/90%
F/38.94 (5.56) yrs/2.13 (0.52) yrs
Group 2: n¼ 10/Somatoform disorder
(SCID-I)/80%F/43.93 (9.96) yrs/3.82
(0.76) yrs
n¼ 10/80%F/39.52 (11.32) yrs
Fayed et al. (2014) 1.5T (GE)/PRESS/(2000/35)/
128/LC model
V PCG/8ml Glu, Glx (Cr, mI, NAA, tCho) Group 1: Migraine/n¼ 33/63.6%F/
45.2 yrs/- Group 2: Fibromyalgia/n¼ 54/
90.7%F/45.1 yrs/-Group 3: Somatoform
disorder/n¼ 10/80%F/44.1 yrs/-Group 4:
Trigeminal cervical neuralgia/n¼ 8/75%
F/46.9yrs/-
n¼ 193/60.6%F/53.2yrs
Feraco et al. (2011) 3T (GE)/PRESS/(2000/35)/128/
LC model
Thal/5.8 ml
VL PFC/9.2 ml
Glu, Glx (tNAA, Cho, mI) n¼ 12/Fibromyalgia (ACR)/92%F/43.2
range (30–54) yrs/-
n¼ 12/92%F/41.3 range (28–56)
yrs
Foerster et al. (2012) 3T (GE)/MEGA-PRESS/(1800/
68)/256/In house-Matlab
program with Gaussian curve
fitting (GABA)
PRESS/(2000/35)/32/LC model
(NAA)
ACC, Occ, R ant and R post Ins/
18ml
GABA
(NAA)
n¼ 16/Fibromyalgia (ACR), >1 yr/100%
F/37.2 (12.8) yrs/>1yr
n¼ 17/100%F/36.1 (11.7) yrs/
>1yr
Gerstner et al. (2012) 3T (GE)/PRESS/(3000/30)/-/LC
model
L and R Ins/12 ml Glu, Gln, Glx (NAA, Cho) n¼ 11/Temporomandibular disorder-
RDC-1- (ongoing pain >3 tender muscle
sites ipsilateral to palpation pain)/91%F/
25.8 (2.33) yrs/range 0.5–7 yrs
n¼ 11/91%F/24.8 (1.20) yrs
(continued on next page)
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Table 2 (continued )
Strength (scanner)/Sequence/
(TR/TE)/Avs/Processing
Region/Voxel size (ml) Neurometabolites Participants: Number/Pain/%Female/
Age/Duration
Controls: Number/%Female/Age
Gonzales de la Aleja
et al. (2013)
3T (GE)/Probe P/(2000/28)/160/
LCModel
Occ/27ml, APC/8ml Glu, Gln, (NAA, Cr, Cho) n¼ 28/Migraine or Migraine with aura
(ICHD2) >2 attacks a month in the last 3
months, >3 yr history/100%/31.74 (8)
yrs/>3yrs
n¼ 19/100%F/31.79 (4.5) yrs
Grachev et al. (2000) 1.5T (GE)/STEAM, Probe-S, PSD/
1500/30/-/Direct from the
scanner
DLPFC/8.1 ml Thal/8/1 ml, CC/
8ml
(Ins/8ml, SM1/7.7 ml OFC/8ml,
Vis cort 8 ml)
Glu, Gln, GABA, (tmI, Glc, Lac, Cr,
NAA, Cho)
n¼ 9/Low back pain >1yr/22.2%F/45 (6)
yrs/9 (5) yrs
n¼ 11/18.2%F/44 (3) yrs
Gussew et al. (2011) 3T (Sie)/PRESS/(2500/40)/-/LC
model
L ant Ins/3 ml, ACC/3.9 ml, L Thal
3.5 ml
Glu, Gln, (NAA, Cr, tCho, mI) n¼ 10/Low back pain >1yr/80%F/range
(22–52 yrs)/range (1–5 yrs)
n¼ 10/80%F/range (22–52 yrs)
Gustin et al. (2014) 3T (P)/MEGA-PRESS/(2000/68)/
100/jMRUI, AMARES (GABA)
-/(2000/29)/-/jMRUI, QUEST
R Thal/8 ml GABA
Glu, Gln, (NAA, Cr, Asp, mI,
GroPCho)
n¼ 12/Spinal cord injury (SCI) with
neuropathic pain, (IASP-SCI)/33.3%F/57
(4) yrs/182 SEM 42 months
n¼ 21/38.1%F/31 (2) yrs
Harfeldt et al. (2018) 3T (Sie)/-/(2000/30)/-/LC model R and L post Ins/2 ml Glu, Glx (NAA, tCr, Cho, m) Group 1: n¼ 19/Temporomandibular
disorder with generalised pain/100%F/43
IQR (40–56) yrs/>3months
Group 2: n¼ 17/Temporomandibular
disorder with local pain/100%F/40 IQR
(30–44) yrs/>3months
n¼ 10/100%F/36 IQR (26–51)
Harper et al. (2018) 3T (P)/MEGA-PRESS/(1800/68)/
256/LC model
PRESS/(2000/33)/32/LC model
R ant Ins, R post Ins, Mid ACC, Mid
Occ (Control Region)/18 ml
GABA
Glx, Glu
n¼ 18/UCPPS- urological chronic pelvic
pain syndrome including interstitial
cystitis, and bladder pain/100%F/34.8 yrs
SD 11/5.9 (6.5) yrs
n¼ 20/100%F/34.7 (12.3) yrs
Harris et al. (2009) 3T (GE)/-/(3000/30)/-/LC model R ant Ins, R post Ins/12ml Glu, Glx, (NAA, MI, Cho, Cr, mI) n¼ 19/Fibromyalgia (ACR), >1 year/
100%F/45.2 (15) yrs/>1yr
n¼ 14/100%F/45.9 (11.1) yrs
Henderson et al. (2013) 3T (P)/MEGA-PRESS/(2000/68)/
200/jMRUI, AMARES
Contra Thal, (R-controls)/8 ml GABA n¼ 23/Painful trigeminal neuropathy
(Liverpool criteria)/82.6%F/46.6 SEM
(2.4)/6.1 SEM (4.6) yrs
n¼ 43/72%F/49.1 SEM (2.5) yrs
Ito et al. (2017) 3T (GE)/-/(2000/30)/96/LC
model
ACC/20 20 40 16ml Glu, Gln, Glx (tCr, mI, NAA) n¼ 56/Chronic pain: neuropathic pain-
narrowing of the spinal canal, trigeminal
neuralgia, intercostal neuralgia,
postoperative neuropathy, radiculopathy,
plexus injury, peripheral nerve injury,
reflex sympathetic dystrophy, diabetic
neuropathy, non-neuropathic-
fibromyalgia, cephalgia, somatoform,
unidentified general or partial pain/67.9%
F/58 range (45–67) yrs/36.5 range
(13.5–74.5) months
n¼ 60/63.3%F/40 range (28–48)
yrs
Janetzki et al. (2016) 3T (Sie)/MEGA-PRESS/(2000/
68)/-/-
PRESS/(1800/30)/-/-
ACC, L Ins/- GABA
Glx (NAA, mI, tCr, tCho)
n¼ 19/Low back pain >3 months/68.4%
F/55.3 yrs/42.1%> 5 years, 52.6%< 5
years, 5.3% unknown
n¼ 19/68.4%F/53.8yrs
Kameda et al. (2018) 3T (GE)/PRESS/(2000/30)/96/
LC model
ACC/16ml Glu, Glx (NAA, Cr, mI) n¼ 60/Low back pain >6 months/61.7%
F/58.8 (16) yrs/-
n¼ 56/62.5%F/39.5 (12.8) yrs
Niddam et al. (2011) 3T (Sie)/PRESS/(2000/30)/128/
LC model
L and R Hippoc/3 ml Glu, Glx (Cho, Cr, mI, NAA) n¼ 15/Irritable bowel syndrome (ROME
III), 53%F/36.6 (11.6)/7.2 (6.8) yrs
n¼ 15/66.7%F/33 (9) yrs
Niddam et al. (2018) 3T (Sie)/MRSI- Proton echo planar
spectroscopic imagine sequence/
(1500/30)/-/LC model
Whole Brain (ACC, Thal, Occ/
8 8)
Glx (Cho, Cr, mI, NAA) Group 1: n¼ 24/Episodic migraine (ICHD-
II)/80%F/37 (7) yrs/17.2 (9.1) yrs
Group 2: n¼ 25/Chronic migraine (ICHD-
II)/70.8%F/33.8 (10) yrs/13.3 (9.1) yrs
n¼ 25/75%F/32.6 (8.3) yrs
Prescot et al. (2009) 4T (V)/2DJ resolved/(2000/
30–260)/16 per TE/LC model
ACC, L Ins/8 ml GABA, Glu, Gln (Full basis set) n¼ 12/Acute episodic migraine/43 (11)
yrs/70%F/23 yrs
n¼ 8/70%F/41 (9) yrs
(continued on next page)
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Table 2 (continued )
Strength (scanner)/Sequence/
(TR/TE)/Avs/Processing
Region/Voxel size (ml) Neurometabolites Participants: Number/Pain/%Female/
Age/Duration
Controls: Number/%Female/Age
Reckziegel et al. (2016) 3T (GE)/PRESS/(2500/105)/
128/LC model
ACC/8–12ml GABA, Glu, Glx, (NAA, tNAA, mI,
tCho)
n¼ 20/Knee osteoarthritis on X-ray, pain
mostly constant in the last month/45%F/
67 (9) yrs/7.7 (4.9) yrs
n¼ 19/42.1%F/59 (9) yrs
Sharma et al. (2011) 3T (Sie)/MRSI- PRESS/(1500/
30)/-/LC model
L, R and Mid SSC/matrix size
16 16; FOV¼ 160mm2
Glx (NAA, Cho) n¼ 11/Chronic low back pain over 4/10/-
%F/33.6 (10.6) yrs/>3months
n¼ 11/-%F/31.4 (13.9) yrs
Siniatchkin et al. (2012) 3T (P)/PRESS/(2000/37)/128/- Primary and Secondary Vis Cort/
8 ml
Glx, GABA (GABA values not
reported) (NAA, Cr)
n¼ 10/Migraine with aura (ICHD-II)/60%
F/19.3 (3.4) yrs/4.2 (4.1) yrs
n¼ 10/60%F/20.3 (3.2) yrs
Valdes et al. (2010) 1.5T (GE)/PRESS/(1500/35)/-/
LC model
L and R Amyg/3.37 ml
L and R Thal/2.25 ml, L and R
PFC/3.37ml
Glu, Gln (NAA, Cho, Cr, mI) n¼ 30/Fibromyalgia (AMR)/100%F/
42.62 (8.76) yrs/151 (120) months
n¼ 30/100%F/43.86 (10.60) yrs
Widerstrom-Noga et al. (2013) 3T (Sie)/PRESS/(2000/30)/256/
LC model
ACC/8.75ml Glx (NAA, tCr, Cho, mI) Group 1: n¼ 31/SCI with low neuropathic
pain/16.12%F/37.5 (13.4) yrs/10.6 (9.07)
yrs
Group 2: n¼ 19/SCI with high
neuropathic pain/26.3%F/40.4 (11.8) yrs/
12 (9.85) yrs
n¼ 24/20.8%F/34.4 (8.6) yrs
Widerstrom-Noga et al. (2015) 3T (Sie)/2D chemical shift
imaging using PRESS/(2000/30)/
4/LC model
L and R Thal/matrix size 8 8;
FOV 160mm
Glx (NAA, Cho, mI) Group 1: n¼ 35/SCI with low neuropathic
pain/20%F/35.7 (12.4) yrs/13.1 (9.7) yrs
Group 2: n¼ 19/SCI with high
neuropathic pain/15.8%F/43 (12.5) yrs/
12 (9.66) yrs
n¼ 24/20.8%F/34.4 (8.6) yrs
Zielman et al. (2017) 7T (P)/Semi-LASER/(5000/30)/
32/LC model
Vis Cor (Occ)/12ml Glu, Gln, Glx (tNAA, tCr, Ins, tCho,
PE, Asp)
Group 1: Migraine without aura (ICHD-
3b)/n¼ 27/51.9%F/35.1 (8.2) yrs/20.9yrs
Group 2: Migraine with aura (ICHD-3b)/
n¼ 23/47.8%F/35 (9.3) yrs/20.6yrs
n¼ 24/50%F/34.8 (8.7) yrs
P- Phillips, Sie- Siemens, GE- General Electric, V- Varian, *Likely Typo, **Not stated-taken from reference, - Not stated, L- Left, R- Right, Ant- Anterior, Post- Posterior, Mid- Midline, V- Ventral, PCG- Posterior Cingulate
Gyrus, Ins- Insula, Occ- Occipital, Thal- Thalamus, APC- Anterior paracingulate cortex, Hippoc- Hippocampus, VL PFC- Ventrolateral Prefrontal Cortex, DLPFC- Dorsolateral Prefrontal Cortex, SM1- Primary sensorimotor
cortex, CC- Cingulate Cortex, OFC- Orbital frontal cortex, Vis cort- Visual Cortex (Occipital Lobe), Amyg- Amygdala, SSC- Somatosensory cortex, GABA-gamma-aminobutyric acid, Glu-glutamate, Gln-glutamine, NAA- N-
acetylaspartate, Cr- Creatine, mI- myoinositol, Cho- Choline, Glx-combined glutamate and glutamine, mI- myoinositol, tCho-total choline, tNAA-total N-acetylaspartate and N-acetylaspartyl glutamate, Glc-glucose, tmI- total
myo-and scyllo-inositol, Lac- Lactate, Asp- Aspartate, GroPCho- Glycerophosphocholine, tCr-total creatine and phosphocreatine, phosphorylethanolamine, SCI- spinal cord injury, ICHD- The international classification of
headache disorders 3 beta, IHS- International headache society, ACR- American college of Rheumatology, ROME III- Diagnostic criteria for irritable bowel syndrome.
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Table 3
Assessment of spectroscopy quality using the MRS-Q tool: un-edited studies.
Parameters Utilisation of quality checks Study design/Post processing QUALITY
>3T Sequenceϕ Data points TE ParametersΔ Shim or FWHM Fit error Data
visualised
Power
calc
Frequency
drift
Partial vol
correction˅
Frequency/
Phase corrected
As Sanie et al. (2016) Y Y <i> ? <i> <i> N Y N N Y N UNSURE
Bathel et al. (2018) Y Y Y Y Y (Thal #) <i> Y Y N N NA Y HIGH (Thal #)
Bigal et al. (2008) Y <i> <i> Y* <i> <i> <i> N N N N <i> UNSURE
Bridge et al. (2015) Y N <i> Y Y Y Y Y N Y Y Y LOW
Di Pietro et al. (2018) Y Y Y Y <i> <i> N Y N N NA N UNSURE
Fayed et al. (2010) N Y <i> Y Y <i> N Y N N N N HIGH
Fayed et al. (2012) N Y <i> Y Y <i> Y Y N N N N HIGH
Fayed et al. (2014) N Y <i> Y Y <i> N Y N N N N HIGH
Feraco et al. (2011) Y Y <i> Y N Y N Y N N NA N LOW
Forester et al. (2012) Y Y <i> Y Y <i> Y Y N N Y N HIGH
Gerstner et al. (2012) Y Y <i> Y <i> <i> N Y N N N N UNSURE
Gonzales de la Aleja et al. (2013) Y Y <i> Y Y <i> Y Y N N Y <i> HIGH
Grachev et al. (2000) N Y <i> Y <i> <i> N Y N N NA N UNSURE
Gussew et al. (2011) Y Y Y Y <i> Y Y Y N Y Y Y UNSURE
Gustin et al. (2014) Y Y Y Y <i> Y N Y N N NA Y UNSURE
Harfeldt et al. (2018) Y <i> <i> Y <i> <i> Y N N N N N UNSURE
Harper et al. (2018) Y Y N Y Y <i> Y Y N N Y N HIGH
Harris et al. (2009) Y Y <i> Y <i> <i> N Y N N Y N UNSURE
Ito et al. (2017) Y Y <i> Y Y <i> N Y N N NA <i> HIGH
Janetzki et al. (2016) Y Y <i> Y <i> <i> N Y N N N <i> UNSURE
Kameda et al. (2018) Y Y <i> Y Y Y Y N N N N N HIGH
Niddam et al. (2011) Y Y Y Y Y Y Y N N Y Y N HIGH
Niddam et al. (2018) Y Y <i> <i> N** Y Y Y N Y Y N UNSURE
Prescot et al. (2009) Y Y~ Y Y Y Y Y Y N N Y Y HIGH
Reckziegal et al. (2016) Y N (Not for GABA) N <i> N (Not GABA) N Y Y Y Y Y N LOW
Sharma et al. (2011) Y Y <i> Y Y** Y Y N N Y Y N HIGH
Siniatchkin et al. (2012) Y Y <i> N Y <i> N Y N N NA Y HIGH
Valdes et al. (2010) N Y <i> Y <i> <i> Y Y N N Y Y UNSURE
Widerstrom et al. (2013) Y Y N Y Y <i> N N N N NA Y HIGH
Widerstrom et al. (2015) Y Y N Y N** <i> N Y N N NA N LOW
Zielman et al. (2017) Y Y Y Y Y <i> Y Y Y N Y Y HIGH
% Yes 83.3 87 23 85 52 29 52 81 6 19 41 33
ϕ¼MEGA-PRESS, MEGA-semi-LASER, other GABA editing; Data points 1024 complex data points from 2000Hz. Short TE¼~20/30ms, Δ¼Adequate parameters 128 Av, 15 15 15 voxel, 3T; 64 Av, 20 20 20
voxel, 3T; 256 Av, 15 15 15 voxel 1.5T; 128 Av, 20 20 20 voxel, 1.533. Partial volume correction ˅ not just grey matter correction, not required for data presented as ratios (NA), Y ¼ Yes, N ¼ No, <i> insufficient
information, * ¼ extracted from cited paper, ** ¼ MRSI, ~ ¼ PRESS based 2DJ, ? ¼ likely error in reporting, # ¼ criteria not fully met.
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A.L. Peek et al. NeuroImage 210 (2020) 116532duplicates, 5505 titles and abstracts were screened for eligibility, with
162 studies deemed eligible for full text screening. Following full text
screening, 127 studies were excluded leaving 35 studies to be included in
the analysis (Fig. 1). Two of which were translated from German and
Japanese prior to inclusion. The 35 studies contributed a total of 140 data
sets for inclusion within the study.
3.2. Study characteristics
3.2.1. Spectroscopy
Twenty-eight studies used 3-T scanners, six studies used 1.5 T, and
two single studies used 4T and 7T respectively. Some studies used both
editing and non-editing: A PRESS sequence or vendor specific variation
was used in 30 analyses including, three of which were implemented
using 2D MRSI (Niddam et al., 2018; Sharma et al., 2011; Wider-
strom-Noga et al., 2015), whilst MEGA-PRESS was used in ten analyses
(Aguila et al., 2015; Bathel et al., 2018; Bednarska et al., 2019; Chan
et al., 2019; Di Pietro et al., 2018; Foerster et al., 2012; Gustin et al.,
2014; Harper et al., 2018; Henderson et al., 2013; Janetzki et al., 2016).
Individual studies used 2DJ resolved (Prescot et al., 2009), semi-LASER
(Zielman et al., 2017), STEAM (Grachev et al., 2000), SPECIAL (Bridge
et al., 2015), and 3D LASER. (Bigal et al., 2008) (Table 2).
3.2.2. Neurometabolites
GABAwas reported in 14 studies (Aguila et al., 2015; Bednarska et al.,
2019; Bigal et al., 2008; Bridge et al., 2015; Chan et al., 2019; Di Pietro
et al., 2018; Foerster et al., 2012; Grachev et al., 2000; Gustin et al., 2014;
Harper et al., 2018; Henderson et al., 2013; Janetzki et al., 2016; Prescot
et al., 2009; Reckziegel et al., 2016), glutamate in 16 (Bridge et al., 2015;
Fayed et al., 2012, 2014; Feraco et al., 2011; Gerstner et al., 2012;
Gonzales de la Aleja et al., 2013; Grachev et al., 2000; Gussew et al.,
2011; Harfeldt et al., 2018; Harper et al., 2018; Harris et al., 2009; Ito
et al., 2017; Kameda et al., 2018; Niddam et al., 2011; Prescot et al.,
2009; Zielman et al., 2017), glutamine in eight (Gerstner et al., 2012;
Gonzales de la Aleja et al., 2013; Grachev et al., 2000; Gussew et al.,
2011; Harris et al., 2009; Harper et al., 2018; Prescot et al., 2009; Ziel-
man et al., 2017) and Glx in 21 (As-Sanie et al., 2016; Bathel et al., 2018;
Bednarska et al., 2019; Chan et al., 2019; Fayed et al., 2010, 2012, 2014;
Feraco et al., 2011; Gerstner et al., 2012; Gussew et al., 2011; Harper
et al., 2018; Harris et al., 2009; Ito et al., 2017; Janetzki et al., 2016;
Kameda et al., 2018; Niddam et al., 2011, 2018; Reckziegel et al., 2016;
Sharma et al., 2011; Siniatchkin et al., 2012; Valdes et al., 2010;
Widerstrom-Noga et al., 2013, 2015; Zielman et al., 2017). None of the
included studies used macromolecular suppression and therefore are
more likely to reflect GABAþ, however for the purpose of this study we
refer to this as GABA. The included studies reported level of neuro-
metabolites as either Institutional units, absolute concentration (e.g.
mmol/l), ratios relative to Cr, or ratios relative to NAA. (Tables 3 and 4).
Raw data was not presented for four studies (Bridge et al., 2015; Kameda
et al., 2018; Niddam et al., 2018; Widerstrom-Noga et al., 2015) and
therefore required callipers for extraction from graphical
representations.
3.2.3. Pain conditions
Migraine was compared to control participants in 11 studies,
(migraine sub-classifications studied included two acute episodic
migraine (Niddam et al., 2018; Prescot et al., 2009), one chronic
migraine (Niddam et al., 2018), four migraine without aura (Aguila et al.,
2015; Bathel et al., 2018; Bigal et al., 2008; Zielman et al., 2017), four
with aura (Bigal et al., 2008; Bridge et al., 2015; Siniatchkin et al., 2012;
Zielman et al., 2017) and three mixed (Chan et al., 2019; Fayed et al.,
2014; Gonzales de la Aleja et al., 2013). Musculoskeletal pain (five
chronic low back pain (Grachev et al., 2000; Gussew et al., 2011; Janetzki
et al., 2016; Kameda et al., 2018; Sharma et al., 2011), one knee osteo-
arthritis (Reckziegel et al., 2016), two temporomandibular joint pain
(Gerstner et al., 2012; Harfeldt et al., 2018)) was compared to control9participants in eight studies. Chronic pain syndromes (seven fibromyal-
gia (Fayed et al., 2010; Fayed et al., 2012; Feraco et al., 2011; Foerster
et al., 2012; Harfeldt et al., 2018; Harris et al., 2009; Valdes et al., 2010),
two somatoform disorder (Fayed et al., 2012, 2014), one chronic wide-
spread pain (Ito et al., 2017)) were compared to control participants in
nine studies and the remaining miscellaneous studies (three spinal cord
injury with neuropathic pain (Gustin et al., 2014; Widerstrom-Noga
et al., 2013; Widerstrom-Noga et al., 2015), one pelvic pain with and
without endometriosis (As-Sanie et al., 2016), one urological chronic
pain (Harper et al., 2018), three with facial neuropathic pain (Di Pietro
et al., 2018; Fayed et al., 2014; Henderson et al., 2013), two painful ir-
ritable bowel syndrome (Bednarska et al., 2019; Niddam et al., 2011)
were compared to control participants in nine studies.
3.2.4. Brain regions
Neurometabolites were investigated across 12 brain regions
including; amygdala, anterior cingulate cortex (ACC), anterior frontal
cortex, cingulate cortex, hippocampus, insula, occipital lobe (including
visual cortex), prefrontal gyrus, posterior cingulate gyrus (PCG),
sensorimotor-cortex, somatosensory cortex, thalamus (Fig. 2). Thirteen
studies reported data from more than one brain region for the review's
primary analysis.
3.3. Quality assessment
3.3.1. AXIS
The quality varied from seven studies (Aguila et al., 2015; As-Sanie
et al., 2016; Bathel et al., 2018; Di Pietro et al., 2018; Niddam et al.,
2011; Valdes et al., 2010; Zielman et al., 2017) satisfying over 80% of the
criteria to four studies (Bridge et al., 2015; Fayed et al., 2014; Harper
et al., 2018; Prescot et al., 2009) satisfying only 50% of criteria. Quality
metrics reported by all studies were the measure used to determine sta-
tistical significance, clear aims, and ethical approval or consent. In
contrast, few studies justified sample size (5/35, 14.28%) or categorised
non-responders (5/35, 14.3%) (Fig. 3). Furthermore, the control of
confounding variables such as limiting the inclusion of participants with
other comorbidities (25/35, 71.4%), controlling for medications (21/35,
60%), and controlling other confounders (15/35, 42.9%) e.g. smoking,
time of day or menstrual cycle were inconsistently addressed across the
studies.
3.3.2. Quality assessment: spectroscopy (MRS-Q)
Most sequences used in the studies (n¼ 21/41 from 35 studies,
51.2%) did not report using adequate spectroscopy parameters. For
example, adequate parameters were used in 20% (n¼ 2/10) of edited,
and 52% (n¼ 16/31) of unedited studies. Of these, 12% (edited) and
35.5% (unedited) studies did not record sufficient details to determine
the overall quality of spectroscopy and allow for reproducing these
studies. Details not reported included averages, voxel size and scanner
strength. Of the 22/41 sequences in studies that did report the parame-
ters used, two (Bridge et al., 2015; Reckziegel et al., 2016) did not use an
appropriate sequence to detect all reported neurometabolites of interest.
Of the studies using sequences edited specifically for GABA (n¼ 8/39),
50% (n¼ 4/8) used the recommended number of averages and 25%
(n¼ 2/8) used an appropriately sized voxel for all regions (Tables 3 and
4).
3.4. Results: primary aim: neurometabolites between pain conditions
3.4.1. GABA level across pain conditions
The level of GABA in migraine was significantly increased compared
with controls (Hedge's G 0.394, 95%CI: 0.095 to 0.0.693, i2¼ 0). In
contrast the level of GABA was significantly decreased in three of the six
miscellaneous studies investigating pelvic pain, trigeminal neuralgia and
painful spinal cord injury compared to controls. GABA level was not
significantly different in musculoskeletal pain (Hedge's G 0.15, 95%CI
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A.L. Peek et al. NeuroImage 210 (2020) 1165320.44 to 0.15, i2¼ 0), or chronic pain syndromes (Hedge's G0.08, 95%
CI 1.61 to 1.46, i2¼ 89.479) compared to controls (Fig. 4).
3.4.2. Glutamate level across pain conditions
The level of glutamate in migraine demonstrated a significant in-
crease compared with controls (Hedges G: 0.45, 95% CI 0.17 to 0.73,
i2¼ 56.79). In contrast glutamate level was significantly decreased in
musculoskeletal conditions compared with controls (Hedge's G 0.262,
95%CI 0.481 to 0.043, i2¼ 0). There was no significant difference
between glutamate level in either chronic pain syndromes or any indi-
vidual study in the miscellaneous pain category compared with controls
(Fig. 5).
3.4.3. Glutamine level across pain conditions
The level of glutamine was not significantly different between any
pain condition and controls. Data compared with controls were migraine
(Hedge's G: 0.309, 95%CI 0.027 to 0.646, i2¼ 57.45) musculoskeletal
pain (Hedge's G: 0.124, 95%CI 0.627 to 0.379, i2¼ 58.87), chronic
pain syndromes (Hedge's G: 0.255, 95%CI0.035 to 0.857 i2¼ 36.25) or
the single study in the miscellaneous pain category (Fig. 6).
3.4.4. Glx level across pain conditions
The level of Glx was significantly increased in chronic pain syndromes
compared with controls (Hedge's G 0.552, 95%CI: 0.332 to 0.773,
i2¼ 56.97). This was not evident in any other pain group compared with
controls. Data compared with controls were migraine (Hedge's G 0.14,
95%CI: 0.16 to 0.43, i2¼ 79.14) musculoskeletal pain (Hedge's G
0.346, 95%CI: 0.169 to 0.861, i2¼ 79.8) and studies of miscellaneous
pain that had a wide spread of results including a significant decrease of
Glx in four studies (two of spinal cord injury, and two of irritable bowel
syndrome), and a significant increase in three studies (two studies of
pelvic pain with and without endometriosis and one of trigeminal neu-
ralgia (Fig. 7).
3.5. Secondary aims
3.5.1. Does spectroscopy quality influence brain neurometabolite levels
Secondary analysis was performed using 64/137 (47%) data sets from
19/33 (57.6%) studies that reported using adequate spectroscopy pa-
rameters (Tables 3 and 4). The analysis using only high-quality studies,
demonstrated that GABA remained significantly increased in migraine
(Hedge's G 0.394, 95%CI: 0.050 to 0.739, i2¼ 6.048) as per the original
analysis. Similarly, as demonstrated in the original analysis, there was no
difference in GABA levels in people with chronic pain syndromes
compared to controls. There were no high-quality spectroscopy studies
that investigated GABA levels for musculoskeletal pain.
When only high-quality studies were analysed, glutamate levels
remained significantly increased in people with migraine (Hedge's G
0.443, 95%CI: 0.154 to 0.732, i2¼ 56.79), and decreased in a single
study of musculoskeletal pain (Hedge's G 0.387, 95%CI: 0.752 to
0.022) compared with controls. There remained no differences in
glutamate levels in chronic pain syndromes compared with controls in
the high-quality studies. Glutamine continued to show no significant
level changes in migraine and there were no high-quality studies for
musculoskeletal pain, and chronic pain syndromes.
Glx was the only neurometabolite to demonstrate a difference when
only high-quality studies were used in the meta-analysis. Whilst the
original analysis demonstrated a non-significant trend towards an in-
crease in Glx levels in people with migraine (Hedge's G 0.135, 95%CI:
0.161 to 0.432, i2¼ 79.14), the high-quality studies demonstrated a
significant increase (Hedge's G 0.657, 95%CI: 0.417 to 0.898,
i2¼ 12.01). The increase in Glx level in chronic pain syndromes
compared to control remained significant when only high-quality studies
were considered (Hedge's G 0.508, 95%CI: 0.292 to 0.723, i2¼ 6.1). Glx
levels in musculoskeletal pain, were not different to the controls in the
high-quality studies in line with the original analysis.10
Fig. 1. PRISMA flow diagram (Moher et al., 2015).
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There was insufficient data from the majority of brain regions to
answer the question; are brain neurometabolite changes influenced by
brain region. Across all neurometabolites and pain conditions, six brain
regions demonstrated significant differences in neurometabolite level
between pain group and control (ACC, PCG, occipital lobe, thalamus,
hippocampus, insula). The number of data sets contributing to these re-
sults varied from one single data set to 11, with the occipital lobe
providing the most comparisons. Pooled data from 11 data sets investi-
gating the occipital lobe demonstrated a significant increase in level of
Glx (Hedge's G 0.452, 95%CI: 0.184 to 0.721, i2¼ 53.12) and glutamate
(Hedge's G 0.572, 95%CI: 0.230–0.904, i2¼ 46.56) in people with
migraine compared with control. However, there were insufficient data
to compare occipital region with other regions in the brain and the oc-
cipital region was not studied in any other pain condition other than
migraine.
The ACCwas the only region to be studied across all neurometabolites
and pain conditions. Single studies demonstrated a significant increase in11glutamine level in the ACC in migraine (Hedge's G 1.148, 95%CI: 0.214
to 2.083) and conversely a decrease in glutamine level in the ACC in
musculoskeletal pain (Hedge's G 1.102, 95%CI: 2.008 to 0.196)
compared with controls. Glx levels in the ACC were significantly
increased in chronic pain syndromes (Hedge's G 0.308, 95%CI: 0.308 to
1.053) compared with controls. All other neurometabolites in other pain
conditions were insignificant. There were insufficient data to compare
levels of neurometabolites between the ACC and other brain region.
When brain neurometabolite levels were averaged across brain re-
gions, there was no significant change except glutamine in migraine,
which remained increased compared to control but reached statistical
significance (Hedge's G 0.350, 95%CI: 0.021 to 0.680).
4. Discussion
The meta-analyses presented here demonstrate that different pain
conditions appear to have unique neurometabolite signatures. In-
dividuals with migraine appeared to have generally increased levels of
Fig. 2. Brain Regions examined in included studies.
Fig. 3. AXIS methodological quality.
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Fig. 4. GABA: analysed by pain conditions.
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pain conditions studied varied in their neurometabolite profile. Four
unique neurometabolite signatures were observed across the different
pain conditions. Some of these observations are consistent with current
theories in chronic pain, others are divergent from them. Hypotheses for
these different observations are discussed below. We also discuss how
results may be influenced by factors such as the quality of reporting and
brain region investigated. This review also highlights that the quality of
reporting 1H-MRS acquisition andmethods is generally poor and calls for
the introduction of a standardized reporting tool.
The neurometabolite signature observed in people with migraine
appears to be unique, people with migraine demonstrated increased
levels of glutamate and GABA compared to control participants, which
was not seen in other conditions. One plausible explanation for higher
glutamate levels occurring in migraine and not in other pain conditions
could be cortical spreading depression, a process uniquely associated
with transient neurological disorders such as migraine and epilepsy
(Cozzolino et al., 2018). Cortical spreading depression is characterized as
a wave of excitation, followed by inhibition which spreads across the
brain. High levels of glutamate have been hypothesized to initiate this
process (Charles and Baca, 2013; Cozzolino et al., 2018). The observed
increase in inhibitory GABA however is more difficult to explain (Aguila
et al., 2015; Bigal et al., 2008). Proposed hypotheses include that GABA
has a protective role in suppressing headaches (Bigal et al., 2008), or that
increased GABA levels reflect a homeostatic response to the increased
glutamate through the GABA metabolic pathway (Pearl et al., 2006).
Alternatively, increased GABA may reflect a pathophysiological13mechanism of migraine which has yet to be fully explained. For example
GABAmay have a role in the regulation of vasodilation (Kocharyan et al.,
2008), or with neurogenic inflammation seen in migraine (Palmer et al.,
1994).
It remains unclear exactly what mechanisms underlie the findings of
increased GABA and Glu in migraine. The downside of MRS is that there
is no specificity as to what pool of GABA is being measured. MRS mea-
sures the presynaptic pool of GABA as a neurotransmitter, and studies
have shown that the GABA measured with MRS is most related to GAD1,
the gene encoding for GAD67 which is predominantly present in the
soma (Marenco et al., 2010). Therefore, GABA is generally thought to
reflect 'inhibitory tone' (Rae, 2014). Increased GABA may be a response
to increased excitation and indeed, several studies (Diener et al., 2015)
suggest drugs targeting GABAA or GABAB-receptor function may be
promising as treatment for pain disorders, including migraine. Endoge-
nous increases in GABA could reflect a similar mechanism to increased
Glu. However, it is possible that dysfunctional GABA signaling through
GABA receptors plays a key role in the emergence of migraine; Studies
have implicated polymorphisms in genes encoding for GABA receptor
subunits in the migraine (Garcia-Martin et al., 2018). Reduced
GABA-receptor function could lead to hyperexcitability of both inhibi-
tory and excitatory neurons and thus, increased neurotransmitter levels.
In contrast, people with chronic pain syndromes (e.g. fibromyalgia)
demonstrated an imbalance between the level of the inhibitory and
excitatory neurometabolites. An imbalance in neurometabolites have
been frequently hypothesized as a mechanism underlying chronic pain
(Chang et al., 2013; Sanaei Nezhad et al., 2017). People with chronic
Fig. 5. Glutamate: analysed by pain conditions.
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ference in inhibitory GABA. This neurometabolite pattern has been
associated with increased pain catastrophizing (Fayed et al., 2012),
suggesting that increased Glx in conditions such as fibromyalgia could
reflect the psychological aspects of living with a widespread chronic pain
syndrome. It has been suggested that the balance of excitatory and
inhibitory tone and its relationship with pain could be explored through
ratios such as GABA to Glutamate. This was not investigated within this
review, but may be considered in future studies, to better understand the
relationship between excitation and inhibition in pain conditions.
Musculoskeletal conditions also demonstrated a unique neuro-
metabolite signature, with a significant decrease in glutamate. However,
only one of the eleven studies used sufficient acquisition parameters such14that this result requires further confirmation. In summary, our observa-
tions together with known observations in the literature suggest there are
distinct neurometabolite signatures for different pain conditions, which
potentially allows for specific disease biomarkers.
Glutamine did not demonstrate significant changes across any of the
pain conditions in the primary analysis. Difficulties in quantifying
Glutamine have been reported, and therefore it is often not reported
alone, except in cases of significant elevation, such as hepatic encepha-
lopathy (Rama Rao et al., 2012). Glutamine's contribution to the Glx
signal is not fully appreciated and can be problematic in conditions,
where the Glu and Gln levels change in opposite directions (Sanaei
Nezhad et al., 2017). To overcome this issue study of the Glu/Gln ratio
has been recommended. Whilst this was not within the scope of this
Fig. 6. Glutamine: analysed by pain conditions.
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into the nature of this relationship in pain conditions.
Our MRS quality appraisal undertaken in this systematic review
suggests that the reporting of MR spectroscopy parameters could be
improved. One-third of all studies did not report key MRS parameters
including the use of an adequately sized voxel, scanner strength and
number of acquisitions. Reporting in studies of GABA in musculoskeletal
pain, would particularly benefit from improvement, where none of the
included studies documented these three key parameters required to
reproduce or evaluate the study. A common methodological limitation in
the spectroscopy studies was not controlling or reporting potential con-
founders such as medication use (Cai et al., 2012; Kuzniecky et al., 2002;
Monteleone et al., 1990), smoking status or substance use (Schulte et al.,
2017), menstrual phase (De Bondt et al., 2015; Epperson et al., 2002,
2005) or alcohol intake (Meyerhoff et al., 2018). The lack of detail makes
it difficult to pool data in meta-analysis such as these and to be certain
about accuracy of reported results in individual studies.
Despite the paucity of reporting, our sensitivity analysis suggests that
adequate spectroscopy parameters were likely used in the majority of
studies. This notion is supported given that results were mostly un-
changed in the sensitivity analysis compared with the original analysis. A
call to improve reporting has been made in other research designs and
imaging modalities. This has led to the successful introduction of
checklists such as PRISMA (Moher et al., 2015) in systematic reviews,
and the CONSORT (Schulz et al., 2010) in randomized controlled trials
and more specifically in functional MRI (Poldrack et al., 2008). Whilst
there have been three white papers recommending the optimal spec-
troscopy parameters for use in MEGA-PRESS (Mullins et al., 2014),
PRESS (Wilson et al., 2019) and Universal (Saleh et al., 2019) this has yet
to be translated into a standardized methodological reporting tool. We
believe the MRS-Q, introduced and developed in this study is an
important first step. Both our finding (only 46% of studies reporting
using adequate parameters) and the call to improve reporting in other
fields suggests the need for the field of MRS to develop a standardized15reporting tool. We propose the MRS-Q could be further validated for this
purpose.
There was insufficient data to establish whether brain region influ-
enced differences in neurometabolite levels. The results presented here
demonstrate that there were inconsistencies in voxel naming, shaping
and positioning. An example is in the ACC where several studies posi-
tioned a long rectangular voxel dorsally along the corpus collosum
(Gussew et al., 2011; Widerstrom-Noga et al., 2013), yet others used a
shorter voxel positioned rostrally (Harper et al., 2018; Prescot et al.,
2009; Reckziegel et al., 2016), without adjusting the nomenclature
accordingly. While we aimed to pool data based on brain region within
pain groups, there were insufficient data to do so. The most frequently
studied brain region was the occipital lobe in people with migraine.
Pooled results for the occipital lobe demonstrated a significant increase
in level of Glx and glutamate in migraine compared to controls. The
occipital lobe has been frequently studied in both headache and mental
health studies partially owing to the high-quality spectra that can be
obtained compared with other brain regions (Puts and Edden, 2012).
Hence, the significant findings found in people with migraine may be due
to the more homogenous field allowing more consistent findings,
resulting in narrower confidence intervals, rather than the region being
clinically different from other regions. Nonetheless, for people with
migraine, the occipital lobe may be relevant to study, due to its's role in
migraine with aura (Charles and Brennan, 2010; Hadjikhani et al., 2001).
Despite these observations, comparison of brain neurometabolites be-
tween brain regions requires further primary studies.
There are several limitations that need to be considered when inter-
preting the findings of this review. Our meta-analyses pooled results from
studies that reported neurometabolite levels using absolute concentra-
tions, institutional units and ratios. This firstly assumes these measures
are reflecting the same variable, and in the case of ratios and institutional
units assumes the creatine and water remain stable. Whilst there is some
evidence that the denominator neurometabolite, most commonly crea-
tine, is indeed stable across various conditions including pain (Chang
Fig. 7. Glx: Analysed by pain conditions.
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A.L. Peek et al. NeuroImage 210 (2020) 116532et al., 2013; Govindaraju et al., 2000; Gussew et al., 2011) there still
remains some uncertainty (Rae, 2014). Steen et al. (2005) were able to
demonstrate equivalence between studies measuring both ratios and
absolute values, further supporting their inclusion in the meta-analysis.
Secondly our primary analysis assumed independence of brain regions
and included data from different brain regions of the same participants,
which may cause over inflation of results. Therefore, we conducted a
post-hoc meta-analysis (not shown) akin to Schur et al. (2016) and Luykx
et al. (2012) and demonstrated that averaging brain neurometabolite
concentration across all brain regions had minimal effect to the overall
results with the exception of glutamine in migraine. Finally, our primary
analysis included studies regardless of quality, the sensitivity analysis
used only studies that reported using acquisition parameters that satis-
fied minimal best practice as determined by published clinical consensus
(Mullins et al., 2014; Wilson et al., 2019).
The accuracy of quantification of GABA and Glutamate is continually
developing, and we can expect to see considerable advances in the field
with improved methods of macromolecule suppression, better analysis
techniques, and further insight into the application of partial volume
correction. Whilst we acknowledge these aspects can create heteroge-
neity and variation in outcome measures the synthesis of information
remains important to help inform future directions in biomarker and pain
research.
In conclusion this meta-analysis serves to catalog what is known in
the field of excitatory and inhibitory neurometabolites in pain condi-
tions. Furthermore, it provides evidence that unique neurometabolite
signatures may exist in different pain conditions. The main limitation in
the field of spectroscopy is failure to adequately report acquisition pa-
rameters and calls for the development and integration of a standardized
reporting tool for magnetic resonance spectroscopy research, allowing
for improved reproducibility and validation of prior work.17Declaration of competing interest
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Research Institute (TRI) Radiographer Research Scholarship, Australia.Appendix 1. Search strategy from OVIDMesh Keywordgamma-aminobutyric acid gaba.mp
glutamic acid glutamate.mp
glutamine Glx
brain chemistry brain adj 3 chemistry.mp
neurotransmitter agents neurotransmitter*neurochemical*
metabolite*
brain metabolite*
neurometabolite*ANDspectrum analysis spectroscop*.mp.
magnetic resonance imaging (magnetic resonance and (imag* or spectroscop*)).mp.
magnetic resonance spectroscopy magnetic resonance spectroscopy.mp
proton magnetic resonancy spectroscopy proton magnetic resonancy spectroscopy.mpmega press
1 hmrs
1h-mrs
in-vivo mrs
Mr
Mrs
mr-specto*
nmr
in-vivo nmrANDpain- exp pain
migraine disorders migraine.mp
back pain exp back pain
low back pain low back pain
fibromyalgia fibromyalgia.mp
chronic pain chronic pain
headache headache
headache disorders primary exp(continued on next column)
A.L. Peek et al. NeuroImage 210 (2020) 116532(continued )Mesh18Keywordheadache disorders, secondary exp
migraine with aura migraine with aura
migraine without aura migraine without aura
musculoskeletal pain exp musculoskeletal pain
whiplash injuries
cancer pain expwhiplash
cancer pain.mpwounds and injuries exp
peripheral nervous system exp
trauma nervous systemAppendix 2. Data extraction sheets
Data extraction sheet 1: Bibliometric data, and clinical characteristics.Data extraction sheet 2: Spectroscopy parameters.Data extraction sheet 3: Results.
Appendix 3. Modified AXIS marking sheet-adapted from Downes et al., 2016QuestionsIntroduction Yes No Don't Know/Comment
1 Were the aims/objectives of the study clear?
Methods
2 Was the study design appropriate for the stated aim(s)?
3 Was the sample size justified?
4 Was the target/reference population clearly defined?
5 Was the sample frame taken from an appropriate population base so that it closely
represented the target/reference population under investigation?
6 Was the selection process likely to select subject/participants that were representative
of the target/reference population under investigation?
7 Were measures undertaken to address and categorise non-responders?
8 Co-morbidities ExcludedWere meds stopped/restricted/or adjusted for
Were other confounders accounted for9(continued on next column)
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QuestionsWere the risk factors and outcome variables measured correctly using instruments/
measurements that had been trialled, piloted or published previously10 Is it clear what was used to determine statistical significance and/or
precision estimates? (e.g. p-values, confidence intervals)1911 Were the methods (including statistical methods) sufficiently described to enable them to be repeated?
Results
12 Were the basic data adequately described?
13 Was there a full justification of any scans excluded from the analysis
14 Were the results internally consistent?
15 Were the results presented for all the analyses described in the methods?
Discussion
16 Were the authors discussions and conclusions justified by the results?
17 Were the limitations of the study discussed?
Other
18 Were there any funding sources or conflicts of interest that may affect the author's interpretation of the results?
19 Was ethical approval or consent of participants attained?References
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